The laboratory is committed to the identification and validation of biomarkers in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), a lethal neurodegenerative disease that affects motor neurons. The laboratory uses proteomic technologies and assays basedon multi-technology platforms.
The levels of biomarkers are measured in cells, tissues and biological fluids from patients and animal models. The functional effects of the same proteins are then investigated in cellular and animal models to identify their role in the onset and progression of the disease.
This research aims to develop innovative therapeutic approaches.
Preclinical study of the pathogenic mechanisms in amyotrophic lateral sclerosis to identify new pharmacological targets
The pathogenic mechanisms leading to ALS onset are currently not completely clarified, and no effective therapies are available. By characterising some experimental models of ALS, it is possible to recognise altered molecular cascades and new potential pharmacological targets. To this purpose, we are developing in vitro (primary cultures and cell lines) and in vivo models (mouse models) expressing specific mutated proteins. Moreover, functional analyses to investigate specific altered molecules as well as pharmacological analyses are performed.
Identification of predictive biomarkers associated with amyotrophic lateral sclerosis
Biomarkers are indicators of disease status or drug response. No validated biomarker is currently available for ALS neither for early diagnosis nor for monitoring disease progression. The identification of proper biomarkers could facilitate clinicians to make accurate therapeutic decisions and even the research for new efficient therapies. To this purpose, the laboratory uses mainly proteomic technologies and automated platforms for immunological assays. Biomarker levels are measured in cells, tissues, plasma, cerebrospinal fluid and extracellular vesicles from patients and animal models. Validation and monitoring of the identified biomarkers are also performed in observational and interventional clinical trials.
International Consensus on Cardiopulmonary Resuscitation.
